{
    "id": 3731,
    "fullName": "CLTC - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CLTC-ALK results from the fusion of CLTC and ALK, creating an oncogenic protein with constitutive kinase activity and the ability to transform cultured cells (PMID: 11485898, PMID: 12750159). CLTC-ALK fusions have been associated with diffuse large B cell lymphomas (PMID: 21494621).",
            "references": [
                {
                    "id": 2190,
                    "pubMedId": 21494621,
                    "title": "Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21494621"
                },
                {
                    "id": 2187,
                    "pubMedId": 11485898,
                    "title": "Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11485898"
                },
                {
                    "id": 2182,
                    "pubMedId": 12750159,
                    "title": "ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12750159"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1213,
        "geneSymbol": "CLTC",
        "terms": [
            "CLTC",
            "CHC",
            "CHC17",
            "CLH-17",
            "CLTCL2",
            "Hc",
            "MRD56"
        ]
    },
    "variant": "CLTC - ALK",
    "createDate": "03/12/2015",
    "updateDate": "04/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 1809,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 demonstrated efficacy by repressing Alk signaling, inducing apoptosis in cultured cells, and promoting tumor regression in cell line xenograft models of diffuse large B-cell lymphoma expressing CLTC-ALK fusions (PMID: 21494621).",
            "molecularProfile": {
                "id": 3533,
                "profileName": "CLTC - ALK"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2190,
                    "pubMedId": 21494621,
                    "title": "Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21494621"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12935,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "CLTC-ALK fusions aid the diagnosis of inflammatory myofibroblastic tumor (NCCN.org).",
            "molecularProfile": {
                "id": 3533,
                "profileName": "CLTC - ALK"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13274,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in stable disease in a patient with inflammatory myofibroblastic tumor harboring CLTC-ALK fusion at 4 months after starting therapy (PMID: 24583837).",
            "molecularProfile": {
                "id": 3533,
                "profileName": "CLTC - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11040,
                    "pubMedId": 24583837,
                    "title": "ALK-positive inflammatory myofibroblastic tumor of the abdomen with widespread microscopic multifocality.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24583837"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3533,
            "profileName": "CLTC - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 17044,
                    "name": "ALK Inhibitor",
                    "profileName": "CLTC - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}